JP2013542720A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013542720A5 JP2013542720A5 JP2013528731A JP2013528731A JP2013542720A5 JP 2013542720 A5 JP2013542720 A5 JP 2013542720A5 JP 2013528731 A JP2013528731 A JP 2013528731A JP 2013528731 A JP2013528731 A JP 2013528731A JP 2013542720 A5 JP2013542720 A5 JP 2013542720A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- antibody
- ephrin
- cancer
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 18
- 102000006396 Ephrin-B2 Human genes 0.000 claims 8
- 108010044090 Ephrin-B2 Proteins 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003550 marker Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 229960002685 biotin Drugs 0.000 claims 2
- 235000020958 biotin Nutrition 0.000 claims 2
- 239000011616 biotin Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000003449 preventive effect Effects 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 108090001008 Avidin Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 102000034287 fluorescent proteins Human genes 0.000 claims 1
- 108091006047 fluorescent proteins Proteins 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000011002 quantification Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ESP201031402 | 2010-09-21 | ||
| ES201031402A ES2378976B1 (es) | 2010-09-21 | 2010-09-21 | Anticuerpo contra ephrin b2 y su uso. |
| PCT/ES2011/070655 WO2012038573A1 (es) | 2010-09-21 | 2011-09-20 | Anticuerpo contra ephrin b2 y su uso |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013542720A JP2013542720A (ja) | 2013-11-28 |
| JP2013542720A5 true JP2013542720A5 (enExample) | 2014-11-06 |
Family
ID=45873482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013528731A Pending JP2013542720A (ja) | 2010-09-21 | 2011-09-20 | 抗エフリン−ｂ２抗体およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9062109B2 (enExample) |
| EP (1) | EP2620449A4 (enExample) |
| JP (1) | JP2013542720A (enExample) |
| KR (1) | KR20140014062A (enExample) |
| CN (1) | CN103237812A (enExample) |
| AU (1) | AU2011306816A1 (enExample) |
| BR (1) | BR112013005977A2 (enExample) |
| CA (1) | CA2812727A1 (enExample) |
| ES (1) | ES2378976B1 (enExample) |
| MX (1) | MX2013003168A (enExample) |
| RU (1) | RU2013118454A (enExample) |
| WO (1) | WO2012038573A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104694477B (zh) * | 2015-03-03 | 2018-04-17 | 西安交通大学 | 一种EphrinB2高表达的重组HEK293细胞及其应用 |
| JP2022516611A (ja) * | 2018-12-28 | 2022-03-01 | ザ ジェネラル ホスピタル コーポレイション | 線維性疾患の治療のための抗エフリン－ｂ２遮断抗体 |
| US20220213214A1 (en) * | 2019-05-14 | 2022-07-07 | Sanford Health | Anti-human ephrin B1 antibodies and uses thereof |
| WO2020242910A1 (en) * | 2019-05-24 | 2020-12-03 | The Regents Of The University Ofcalifornia | Compositions and methods for treating cancer |
| TW202547871A (zh) * | 2024-03-27 | 2025-12-16 | 美商麥第爾醫療公司 | 抗ｅｐｈｒｉｎ ｂ２抗體及使用方法 |
| CN121159668A (zh) * | 2025-09-12 | 2025-12-19 | 北京威斯克生物医药有限公司 | Ephrin-B2重组蛋白及其疫苗、制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004260884B2 (en) * | 2003-07-22 | 2009-11-19 | Crucell Holland B.V. | Binding molecules against SARS-coronavirus and uses thereof |
| JP2007320850A (ja) * | 2004-08-24 | 2007-12-13 | Kyowa Hakko Kogyo Co Ltd | 抗エフリンｂ２抗体 |
| EP1954720A1 (en) * | 2005-10-31 | 2008-08-13 | The Government of the United States of America, as represented by the Secretary of Health and Human Services, National Institutes of Health | Antibodies and immunotoxins that target human glycoprotein nmb |
| RU2451031C2 (ru) * | 2006-01-20 | 2012-05-20 | Дженентек, Инк. | Антитела к эфрину в2 и способы их применения |
| PL1972637T3 (pl) * | 2007-03-19 | 2012-01-31 | Univ Stuttgart | Antagoniści selektywni wobec huTNFR1 |
| WO2010019565A2 (en) * | 2008-08-12 | 2010-02-18 | Medlmmune, Llc | Anti-ephrin b2 antibodies and their use in treatment of disease |
-
2010
- 2010-09-21 ES ES201031402A patent/ES2378976B1/es not_active Expired - Fee Related
-
2011
- 2011-09-20 KR KR1020137007045A patent/KR20140014062A/ko not_active Withdrawn
- 2011-09-20 US US13/824,171 patent/US9062109B2/en not_active Expired - Fee Related
- 2011-09-20 CN CN2011800534643A patent/CN103237812A/zh active Pending
- 2011-09-20 MX MX2013003168A patent/MX2013003168A/es not_active Application Discontinuation
- 2011-09-20 RU RU2013118454/10A patent/RU2013118454A/ru not_active Application Discontinuation
- 2011-09-20 JP JP2013528731A patent/JP2013542720A/ja active Pending
- 2011-09-20 CA CA2812727A patent/CA2812727A1/en not_active Abandoned
- 2011-09-20 EP EP11826446.4A patent/EP2620449A4/en not_active Withdrawn
- 2011-09-20 BR BR112013005977A patent/BR112013005977A2/pt not_active IP Right Cessation
- 2011-09-20 AU AU2011306816A patent/AU2011306816A1/en not_active Withdrawn
- 2011-09-20 WO PCT/ES2011/070655 patent/WO2012038573A1/es not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells | |
| Delcourt et al. | The protein coded by a short open reading frame, not by the annotated coding sequence, is the main gene product of the dual-coding gene MIEF1 | |
| Cao et al. | The heterogeneous nuclear ribonucleoprotein hnRNPM inhibits RNA virus-triggered innate immunity by antagonizing RNA sensing of RIG-I-like receptors | |
| JP2011188853A5 (enExample) | ||
| JP2016505826A (ja) | スクリーニングの方法 | |
| JP2014239695A5 (enExample) | ||
| Khosla et al. | miR‐26b‐5p helps in EpCAM+ cancer stem cells maintenance via HSC71/HSPA8 and augments malignant features in HCC | |
| CN104830867A (zh) | 一种能够特异性结合癌细胞中的dkk1蛋白的适配子 | |
| Shen et al. | Evaluation of phage display discovered peptides as ligands for prostate-specific membrane antigen (PSMA) | |
| JP2009539082A5 (enExample) | ||
| RU2013118454A (ru) | Антитело к эфрину в2 и его применение | |
| JP2014503180A5 (enExample) | ||
| JP2017538412A5 (enExample) | ||
| Bhatter et al. | Arginine methylation augments Sbp1 function in translation repression and decapping | |
| FI3430043T3 (fi) | Anti-TNFalfa -vasta-aineita ja niiden funktionaalisia fragmentteja | |
| JP2010528584A5 (enExample) | ||
| JP6609570B2 (ja) | がんを検出するための方法およびバイオマーカー | |
| JP2012513584A5 (enExample) | ||
| WO2016164357A1 (en) | Phages for biomarker capture and methods of use | |
| US20220365089A1 (en) | Cancer diagnostic | |
| US10774122B2 (en) | ERG targeted therapy | |
| JP2018520366A5 (enExample) | ||
| JP2009523004A5 (enExample) | ||
| CA3103147A1 (en) | Biomarkers for urothelial carcinoma and applications thereof | |
| KR20160050727A (ko) | 리포칼린 2 단백질에 특이적으로 결합하는 dna 앱타머 및 이의 용도 |